ARTICLE | Product Development
Genentech takes the wheel
Why Roche could lean on Genentech to gain lost ground in cancer immunotherapy
February 9, 2019 12:41 AM UTC
Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at least three positive moves that could help it recover the lost ground.
The Genentech Inc. unit has established itself as Roche’s primary growth driver, serving as its primary U.S. commercial engine -- a market that is gaining in importance to the pharma’s balance sheet...